Enlivex Therapeutics Ltd. (ENLV)
Enlivex Therapeutics Statistics
Share Statistics
Enlivex Therapeutics has 21.99M shares outstanding. The number of shares has increased by 5.36% in one year.
| Shares Outstanding | 21.99M |
| Shares Change (YoY) | 5.36% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 16.03% |
| Shares Floating | 19.34M |
| Failed to Deliver (FTD) Shares | 393 |
| FTD / Avg. Volume | 0.31% |
Short Selling Information
The latest short interest is 104.42K, so 0.49% of the outstanding shares have been sold short.
| Short Interest | 104.42K |
| Short % of Shares Out | 0.49% |
| Short % of Float | 0.52% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -1.73 and the forward PE ratio is -1.46. Enlivex Therapeutics's PEG ratio is 0.05.
| PE Ratio | -1.73 |
| Forward PE | -1.46 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.67 |
| P/FCF Ratio | -2.11 |
| PEG Ratio | 0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Enlivex Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.57, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.57 |
| Quick Ratio | 5.57 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.04 |
| Debt / FCF | -0.04 |
| Interest Coverage | -2099.64 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-409.41K |
| Employee Count | 71 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -34.85% in the last 52 weeks. The beta is 0.84, so Enlivex Therapeutics's price volatility has been higher than the market average.
| Beta | 0.84 |
| 52-Week Price Change | -34.85% |
| 50-Day Moving Average | 1.03 |
| 200-Day Moving Average | 1.23 |
| Relative Strength Index (RSI) | 35.28 |
| Average Volume (20 Days) | 127.49K |
Income Statement
| Revenue | n/a |
| Gross Profit | -835K |
| Operating Income | -29.39M |
| Net Income | -29.07M |
| EBITDA | -28.22M |
| EBIT | -29.05M |
| Earnings Per Share (EPS) | -1.56 |
Balance Sheet
The company has 813K in cash and 1.03M in debt, giving a net cash position of -219K.
| Cash & Cash Equivalents | 813K |
| Total Debt | 1.03M |
| Net Cash | -219K |
| Retained Earnings | -112.09M |
| Total Assets | 29.8M |
| Working Capital | 24.32M |
Cash Flow
In the last 12 months, operating cash flow was -23.52M and capital expenditures -236K, giving a free cash flow of -23.76M.
| Operating Cash Flow | -23.52M |
| Capital Expenditures | -236K |
| Free Cash Flow | -23.76M |
| FCF Per Share | -1.28 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ENLV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ENLV is $13, which is 1411.6% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13 |
| Price Target Difference | 1411.6% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Mar 6, 2019. It was a backward split with a ratio of 1:8.
| Last Split Date | Mar 6, 2019 |
| Split Type | backward |
| Split Ratio | 1:8 |
Scores
| Altman Z-Score | -2.9 |
| Piotroski F-Score | 2 |